332 related articles for article (PubMed ID: 22720323)
21. Hospitalization for Respiratory Syncytial Virus Bronchiolitis in the Palivizumab Prophylaxis Era: Need for Reconsideration of Preventive Timing and Eligibility.
Oz-Alcalay L; Ashkenazi S; Glatman-Freedman A; Weisman-Demri S; Lowenthal A; Livni G
Isr Med Assoc J; 2019 Feb; 21(2):110-115. PubMed ID: 30772962
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness of Palivizumab Against Respiratory Syncytial Virus Hospitalization Among Preterm Infants in a Setting With Year-Round Circulation.
Yeo KT; Yung CF; Khoo PC; Saffari SE; Sng JSP; How MS; Quek BH
J Infect Dis; 2021 Jul; 224(2):279-287. PubMed ID: 33274362
[TBL] [Abstract][Full Text] [Related]
23. Hospitalization for bronchiolitis in children aged ≤ 1year, Southern Italy, year 2021: need for new preventive strategies?
Baldassarre ME; Loconsole D; Centrone F; Caselli D; Martire B; Quartulli L; Acquafredda A; D'Amato G; Maffei G; Latorre G; Riganti A; Di Noia M; Chironna M; Laforgia N
Ital J Pediatr; 2023 Jun; 49(1):66. PubMed ID: 37280662
[TBL] [Abstract][Full Text] [Related]
24. Preventing RSV bronchiolitis in vulnerable infants: the role of palivizumab.
Fitzgerald DA
Paediatr Respir Rev; 2009 Sep; 10(3):143-7. PubMed ID: 19651385
[TBL] [Abstract][Full Text] [Related]
25. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
;
Pediatrics; 2014 Aug; 134(2):e620-38. PubMed ID: 25070304
[TBL] [Abstract][Full Text] [Related]
26. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
;
Pediatrics; 2014 Aug; 134(2):415-20. PubMed ID: 25070315
[TBL] [Abstract][Full Text] [Related]
27. [Chemoprophylaxis with palivizumab in Andalusia (Spain). Results of the 2000-2001 respiratory syncytial virus epidemic].
Grupo de Hospitales Benazuza
An Esp Pediatr; 2002 Apr; 56(4):293-7. PubMed ID: 11927095
[TBL] [Abstract][Full Text] [Related]
28. Respiratory syncytial virus bronchiolitis in congenital diaphragmatic hernia: A systematic review of prevalence rates and palivizumab prophylaxis.
Lewis L; Sinha I; Losty PD
Pediatr Pulmonol; 2022 Jan; 57(1):239-244. PubMed ID: 34617409
[TBL] [Abstract][Full Text] [Related]
29. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
[TBL] [Abstract][Full Text] [Related]
30. RSV prophylaxis guideline changes and outcomes in children with congenital heart disease.
Walpert AS; Thomas ID; Lowe MC; Seckeler MD
Congenit Heart Dis; 2018 May; 13(3):428-431. PubMed ID: 29436781
[TBL] [Abstract][Full Text] [Related]
31. [Impact of a targeted educational intervention on respiratory syncytial virus bronchiolitis prevention in full-term and preterm infants].
Bernard L; Lecomte B; Pereira B; Proux A; Boyer A; Sautou V
Arch Pediatr; 2015 Feb; 22(2):146-53. PubMed ID: 25534557
[TBL] [Abstract][Full Text] [Related]
32. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants.
Blanken MO; Rovers MM; Molenaar JM; Winkler-Seinstra PL; Meijer A; Kimpen JL; Bont L;
N Engl J Med; 2013 May; 368(19):1791-9. PubMed ID: 23656644
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.
Hampp C; Kauf TL; Saidi AS; Winterstein AG
Arch Pediatr Adolesc Med; 2011 Jun; 165(6):498-505. PubMed ID: 21300647
[TBL] [Abstract][Full Text] [Related]
34. Prevention of respiratory syncytial virus infection with palivizumab.
Thomas M; Bedford-Russell A; Sharland M
Monaldi Arch Chest Dis; 2000 Aug; 55(4):333-8. PubMed ID: 11057088
[TBL] [Abstract][Full Text] [Related]
35. Respiratory syncytial virus immune globulin: decisions and costs.
Barton LL; Grant KL; Lemen RJ
Pediatr Pulmonol; 2001 Jul; 32(1):20-8. PubMed ID: 11416872
[TBL] [Abstract][Full Text] [Related]
36. Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? - a cost-utility analysis.
Ginsberg GM; Somekh E; Schlesinger Y
Isr J Health Policy Res; 2018 Dec; 7(1):63. PubMed ID: 30554570
[TBL] [Abstract][Full Text] [Related]
37. Apnea with RSV infection in three infants receiving palivizumab.
Del Vecchio MT
Pediatr Int; 2013 Dec; 55(6):e159-61. PubMed ID: 24330303
[TBL] [Abstract][Full Text] [Related]
38. Impact of palivizumab on RSV hospitalizations for children with hemodynamically significant congenital heart disease.
Chang RK; Chen AY
Pediatr Cardiol; 2010 Jan; 31(1):90-5. PubMed ID: 19915892
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of palivizumab prophylaxis among infants with congenital heart disease: A case control study.
Ozyurt A; Narin N; Baykan A; Argun M; Pamukcu O; Zararsiz G; Sunkak S; Uzum K
Pediatr Pulmonol; 2015 Oct; 50(10):1025-32. PubMed ID: 25156973
[TBL] [Abstract][Full Text] [Related]
40. Epidemiology of hospitalization for acute bronchiolitis in children: differences between RSV and non-RSV bronchiolitis.
Hervás D; Reina J; Yañez A; del Valle JM; Figuerola J; Hervás JA
Eur J Clin Microbiol Infect Dis; 2012 Aug; 31(8):1975-81. PubMed ID: 22240853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
